Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Merck Plans Wilmington, Delaware, Biologics Operations

05/23/2025
Multinational science and technology company Merck plans to establish operations in Wilmington, Delaware. The approximately $900 million project is expected to create more than 500 jobs.

The investment will include the construction of a 470,000-square-foot biologics center of excellence, located at the Chestnut Run Innovation and Science Park, which will feature laboratory, manufacturing and warehouse capabilities. Operations are scheduled to begin by 2028.

“The decision to build a new biologics facility in Wilmington demonstrates our commitment to advancing U.S. manufacturing and partnering in communities where our employees live and work,” said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. “As a hub for life science, research and development, and pharmaceutical manufacturing, CRISP offers unparalleled opportunities for future expansion.”

Merck, doing business as Merck Sharp & Dohme or MSD outside the U.S. and Canada, develops and produces medicines, vaccines, biologic therapies and animal health products. The company’s blockbuster products include cancer immunotherapy, anti-diabetic medications, and vaccines for HPV and chickenpox.

“This new site in Delaware is on the cutting edge of innovation, helping lead the way as we transform medicine and technology,” noted Delaware Gov. Matt Meyer. “Merck is pioneering the next generation of care right here in Wilmington, and they couldn’t have picked a better place to do it. The positive impact this will have on Wilmington and the state of Delaware is exciting, and this is just the beginning.”

Exclusive Research